Zoetis (ZTS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
8 Apr, 2026Executive summary
Annual shareholder meeting scheduled for May 20, 2026, with virtual attendance available.
Shareholders are invited to vote on key proposals, including director elections and executive compensation.
Voting matters and shareholder proposals
Election of 12 directors is on the agenda, with all nominees recommended by the board.
Advisory vote on executive compensation and on the frequency of future say-on-pay votes.
Ratification of KPMG LLP as independent registered public accounting firm for 2026.
Shareholder proposal to permit shareholder action by written consent.
Board of directors and corporate governance
Board recommends all director nominees for election.
Board provides recommendations on all voting items, supporting management proposals and opposing the shareholder proposal.
Latest events from Zoetis
- Driving animal health innovation and growth with a diverse portfolio and global scale.ZTS
Corporate presentation8 Apr 2026 - 2026 proxy details strong growth, governance, and sustainability, with key votes on directors and pay.ZTS
Proxy filing8 Apr 2026 - Growth in 2026 will be led by parasiticides, innovation in long-acting therapies, and expanding franchises.ZTS
2026 KeyBanc Capital Markets Healthcare Forum17 Mar 2026 - Triple combination parasiticides and livestock drive growth amid resilient global demand.ZTS
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - Strong product innovation and market expansion drive growth amid resilient pet health spending.ZTS
Leerink Global Healthcare Conference 20269 Mar 2026 - 2026 guidance reflects resilience, innovation, and a synchronized global reporting calendar.ZTS
BofA Securities Animal Health Summit26 Feb 2026 - 2025 saw 6% organic growth, robust franchises, and strong 2026 guidance for further gains.ZTS
Q4 202512 Feb 2026 - Strong Q1 growth, robust innovation pipeline, and expanding alternative channels drive outlook.ZTS
Stifel Jaws & Paws Conference 20253 Feb 2026 - Q2 revenue up 11% operationally, adjusted net income up 18%, and $6B buyback approved.ZTS
Q2 20242 Feb 2026